The Pharmacological Characterisation of Pilocarpine-induced Purposeless Chewing Behaviour in the Rat

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1988 Jan 1

PMID 2906443

Citations 11

Authors

B R Stewart

P Jenner

C D Marsden

Affiliations

Soon will be listed here.

Abstract

Purposeless chewing in rats was induced by the acute administration of the cholinergic agonist pilocarpine or by physostigmine. Pilocarpine-induced chewing was antagonised by the centrally acting anticholinergic drugs scopolamine, benzhexol and secoverine, but not by the peripherally acting anticholinergic drug methylscopolamine. Both benzhexol and secoverine caused dose-dependent inhibition of pilocarpine-induced chewing. The D-2 antagonist sulpiride and the D-1 antagonist SCH 23390 did not inhibit pilocarpine-induced chewing. The non-selective neuroleptics pimozide, trifluoperazine and thioridazine also were inactive. In contrast, clozapine caused a dose-related inhibition of pilocarpine-induced chewing. The alpha-1 antagonist prazosin, the alpha-2 antagonist idazoxan, the beta-antagonists propranolol and metoprolol and the H-1 antagonist mepyramine did not reduce pilocarpine-induced chewing. Purposeless chewing behaviour induced by pilocarpine was reduced in a dose-related manner by the administration of the 5-HT antagonists methiothepin and mianserin, but not by spiperone or ketanserin. These data confirm that pilocarpine-induced chewing behaviour in the rat is a model of central cholinergic activity, but suggest that a serotonergic component may be involved in the mediation of this behaviour.

Citing Articles

Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.

Jackson M, Swart T, Pearce R, Jenner P J Neural Transm (Vienna). 2013; 121(2):163-9.

PMID: 23959162 DOI: 10.1007/s00702-013-1082-1.

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover K, Betz A, Weber S, Bibbiani F, Kielaite A, Weiner D Pharmacol Biochem Behav. 2008; 90(4):540-4.

PMID: 18534670 PMC: 2806670. DOI: 10.1016/j.pbb.2008.04.010.

The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.

Betz A, McLaughlin P, Burgos M, Weber S, Salamone J Psychopharmacology (Berl). 2007; 194(3):347-59.

PMID: 17594079 DOI: 10.1007/s00213-007-0844-6.

Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Wolf W, Bieganski G, Guillen V, Mignon L Psychopharmacology (Berl). 2005; 182(1):84-94.

PMID: 15986194 DOI: 10.1007/s00213-005-0033-4.

Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Kinon B, Lieberman J Psychopharmacology (Berl). 1996; 124(1-2):2-34.

PMID: 8935797 DOI: 10.1007/BF02245602.

References

Perry E, Perry R, Blessed G, Tomlinson B . Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977; 1(8004):189. DOI: 10.1016/s0140-6736(77)91780-9. View

Davies P, Maloney A . Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2(8000):1403. DOI: 10.1016/s0140-6736(76)91936-x. View

Tricklebank M, Middlemiss D, Neill J . Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat. Neuropharmacology. 1986; 25(8):877-86. DOI: 10.1016/0028-3908(86)90014-6. View

Rupniak N, Jenner P, Marsden C . Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology (Berl). 1985; 85(1):71-9. DOI: 10.1007/BF00427326. View

Meldrum B, Anlezark G, Marsden C . Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain. 1977; 100(2):313-26. DOI: 10.1093/brain/100.2.313. View

Worms P . Behavioral pharmacology of the benzamides as compared to standard neuroleptics. Adv Biochem Psychopharmacol. 1982; 35:7-16. View

Salamone J, Lalies M, Channell S, Iversen S . Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology (Berl). 1986; 88(4):467-71. DOI: 10.1007/BF00178508. View

Porsolt R, JALFRE M . Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berl). 1981; 75(1):16-21. DOI: 10.1007/BF00433494. View

Davis A, Jenner P, Marsden C . A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine. Br J Pharmacol. 1986; 87(1):129-37. PMC: 1916888. DOI: 10.1111/j.1476-5381.1986.tb10164.x. View

10.

Marsden C, Marion M, Quinn N . The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry. 1984; 47(11):1166-73. PMC: 1028082. DOI: 10.1136/jnnp.47.11.1166. View

11.

Wettstein A, Spiegel R . Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology (Berl). 1984; 84(4):572-3. DOI: 10.1007/BF00431470. View

12.

Costain D, Green A . beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. Br J Pharmacol. 1978; 64(2):193-200. PMC: 1668317. DOI: 10.1111/j.1476-5381.1978.tb17289.x. View

13.

Summers W, Majovski L, Marsh G, Tachiki K, Kling A . Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986; 315(20):1241-5. DOI: 10.1056/NEJM198611133152001. View

14.

Gower A, Marriott A . Pharmacological evidence for the subclassification of central dopamine receptors in the rat. Br J Pharmacol. 1982; 77(1):185-93. PMC: 2044655. DOI: 10.1111/j.1476-5381.1982.tb09285.x. View

15.

Tricklebank M, Forler C, Fozard J . The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 1984; 106(2):271-82. DOI: 10.1016/0014-2999(84)90714-3. View

16.

Bowen D, Smith C, White P, Davison A . Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976; 99(3):459-96. DOI: 10.1093/brain/99.3.459. View

17.

Casey D, Gerlach J, Christensson E . Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology (Berl). 1980; 70(1):83-7. DOI: 10.1007/BF00432375. View

18.

Bradley P, Engel G, Feniuk W, Fozard J, Humphrey P, Middlemiss D . Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986; 25(6):563-76. DOI: 10.1016/0028-3908(86)90207-8. View

19.

Clow A, Jenner P, Marsden C . Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol. 1979; 57(4):365-75. DOI: 10.1016/0014-2999(79)90499-0. View

20.

Fahn S . Generalized dystonia: concept and treatment. Clin Neuropharmacol. 1986; 9 Suppl 2:S37-48. View